Effects of Thalidomide on QTc, Inotropy, and Lusitropy in the Isolated Guinea Pig Heart

Cardiovascular Toxicology

Volumn 4, Issue 1, 2004, Pages 29-36

  Hamlin, Robert L ^a,d   Kijtawornrat, Anusak ^a   Keene, Bruce W ^b   Nakayama, Tomohiro ^a   Nakayama, Hitomi ^a   Hamlin, David M ^c   Arnold, Tammy A ^c  

^a OHIO STATE UNIVERSITY   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c QTest Laboratories Inc   (United States)

^d NONE   (United States)

Author keywords

Cardiac toxicity; Inotropy; Lusitropy; QTc; Thalidomide; Torsadogenicity

Indexed keywords

THALIDOMIDE;

ANIMAL TISSUE; ARRHYTHMOGENESIS; ARTICLE; CARDIOTOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; GUINEA PIG; HEART FUNCTION; HEART LEFT VENTRICLE CONTRACTILITY; HEART PERFUSION; INOTROPISM; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; RR INTERVAL; TORSADE DES POINTES;

ANIMALS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; GUINEA PIGS; HEART; HEART RATE; MALE; MYOCARDIAL CONTRACTION; TERATOGENS; THALIDOMIDE; VENTRICULAR FUNCTION, LEFT;

ANIMALIA; CAVIA PORCELLUS; SUS SCROFA;

EID: 1942422296     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1385/CT:4:1:29     Document Type: Article

References (40)

1. Curran, W.J. and Hyg, S.M. (1971). The thalidomide tragedy in Germany: the end of a historic medicolegal trial. N. Engl. J. Med. 284:481-482.
2. Kelsey, F.O. (1998). Thalidomide update: regulatory aspects. Teratology 38:221-226.
3. McBride, W.G. (1961). Thalidomide and congenital abnormalities. Lancet 2:1358.
4. Ostraat, O., Riesbeck, K., Qi, Z., Eriksson, T., Schatz, H., and Ekberg, H. (1996). Thalidomide prolonged graft survival in a rat cardiac transplant model but had no inhibitory effect on lymphocyte function in vitro. Transp. Immunol. 4:117-125.
5. Miller, J.L. (1997). Thalidomide recommended for approval under tight restrictions. Am. J. Health-Sys. Pharm. 54:2270-2280.
6. Hastings, R.C., Trautman, J. R., Enna, C.D., and Jacobson, R.R. (1970). Thalidomide in the treatment of erythema nodosum leprosum: with a note on selected laboratory abnormalities in erythema nodosum leprosum. Clin. Pharmacol. Ther. 11:481-487.
7. Thalomid capsules [package insert]. (2001). Warren, NJ: Celgene Corporation.
8. Hellmann, K., Duyke, D.J., and Tucker, D.F. (1965). Prolongation of skin homograft survival by thalidomide. BMJ 2:687-689.
9. Anderson, K.C., Hamblin, T.J., and Traynor, A. (1999). Management of multiple myeloma today. Semin. Hematol. 36:3-8.
10. Haslett, P., Hempstead, M., Seidman, C., Diakun, J., Vasquez, D., Freedman, V.H., et al. (1997). The metabolic and immunologic effects of short term thalidomide treatment if patients infected with the human immunodeficiency virus. AIDS Res. Hum. Retrovir. 13:1047-1054.
11. D'Amato, R.J., Loughnan, M.S., Flynn, E., and Folkman, J. (1994). Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA 91:4082-4085.
12. Davey, P.P. and Ashrafian, H. (2000). New therapies for heart failure: is thalidomide the answer? QJM 93:305-311.
13. Clark, T.E., Edom, N., Larson, J., and Lindsey, L.J. (2001). Thalomid® (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. Drug Safety 24:87-117.
14. Zimmer, H.G. (1998). The isolated perfused heart and its pioneers. News Physiol. Sci. 13:203-210.
15. Fridericia, L. (1920). Die systoledaver in electrokardiogramm bei normalen menshen und bei herzfranken. Acta Med. Scand. 53:469-486.
16. Mason, D., Soann, J., and Zelis, R. (1970). Quantification of the contractile state of the intact human heart. Am. J. Cardiol. 26:248-257.
17. Gaasch, W. and Zile, M. (1984). Evaluation of myocardial function in cardiomyopathic states. Prog. Cardiovasc. Dis. 27:115-132.
18. Weiss, J.L., Fredericksen, J.W., and Weisfeldt, M.L. (1976). Hemodynamic determinants of the time-course of fall in canine left ventricular pressure. J. Clin. Invest. 58:751-760.
19. Bowditch, H.P. (1871). Ueber die Eigenthumlichkeiten der Reizbarkeit, welche die Muskelfasern des Herzens zeigen. Ber. Math. Phys. Sachs. Gesellsch. Wissensch. (Leipzig) 23:652-689.
20. Balser, J.R., Bennett, P.B., and Roden, D.M. (1990). Time-dependent outward current in guinea pig ventricular myocytes. J. Gen. Physiol. 96:835-863.
21. Bicer, S., Patchell, J.S., Hamlin, D.M., and Hamlin, R.L. (2002). Acute effects of escalating doses of amiodarone in isolated guinea pig hearts. J. Vet. Pharmacol. Therap. 25:221-226.
22. Boss-Baumgartner, S., Scholtysik, G., Schaad, A., and Hess, T. (1997). Conditioning guinea pig heart in vitro for torsade de pointes arrhythmias. Exp. Clin. Cardiol. 2:191-194.
23. Bunger, R., Haddy, F.J., Querengasser, A., and Gerlach, E. (1975). An isolated guinea pig heart preparation with in vivo like features. Pflugers. Arch. 353:317-326.
24. Gerhardy, A., Scholtysik, G., Schaad, A., Haltiner, R., and Hess, T. (1998). Generating and influencing torsades de pointes-like polymorphic ventricular tachycardia in isolated guinea pig hearts. Basic Res. Cardiol. 93:285-294.
25. Backx, P.H. and Marban, E. (1993). Background potassium current active during the plateau of the action potential in guinea pig ventricular myocytes. Cir. Res. 72:890-900.
26. Adamantidis, M.M., Dumotier, B.M., Caron, J.F., and Bordet, R. (1998). Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarization in rabbit Purkinje fibers. Fundam. Clin. Pharmacol. 12:70-76.
27. Alousi, A.A., Canter, J.M., Montenaro, M.J., Fort, D.J., and Ferrari, R.A. (1983). Cardiotonic activity of milrinone, a new and potent cardiac by pyridine in the normal and failing heart of experimental animals. J. Cardiovasc. Pharmacol. 5:792-803.
28. Bicer, S., Nakayama, H., and Nakayama, T. (2001). Effects of chronic, oral amiodarone on left ventricular pressure, electrocardiograms, and action potentials from myocardium in vivo and from Purkinje fibers in vitro. J. Vet. Pharmacol. Ther. 2:325-333.
29. Dascal, N. (1987). The use of Xenopus oocytes for the study of ion channels. Crit. Rev. Biochem. 22:341-356.
30. Yan, G.X., Shimizu, W., and Antzelevitch, C. (1998). Characteristics and distribution of M cells in arterially perfused canine left ventricular wedge preparations. Circulation 98:1921-1927.
31. Hamlin, R.L., Cruze, C.A., Mittelstadt, S.W., Kijtawomrat, A., Keene, B.W., Roche, B.M., et al. Sensitivity and specificity of the isolated-perfused guinea pig heart to test for drug-induced lengthening of QTc. J. Pharmacol. Toxicol. Methods 49:15-23.
32. Eriksson, T., Bjorkman, S., Roth, B., Fyge, A., and Hoglund, P. (1998). Enantiomers of thalidomide-blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. Chirality 10:223-228.
33. Redfern, W.S., Carlsson, L., Davis, A.S., Lynch, W.G., Mackenzie, I., Palethorpe, S., et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58:32-45.
34. Ancer, B.M. (2002). New concerns about thalidomide. Obstet. Gynecol. 99:125-128.
35. Mujagic, H., Chabner, B., and Mujagic, Z. (2002). Mechanisms of action and potential therapeutic uses of thalidomide. Croat. Met. J. 43:274-285.
36. Lutwak-Mann, C., Schmidt, K., and Keberle, H. (1967). Thalidomide in rabbit semen. Nature 214:1018-1020.
37. Valorie, A.M. (2000). Thalidomide: a new beginning. Cancer Pract. 8:101-103.
38. DiSalvo, T.G. and O'Gara, P.T. (1995). Torsades de pointes caused by high dose intravenous haloperidol in cardiac patients. Clin. Cardiol. 18:285-290.
39. Antzelevitch, C., Sun, Z.Q., Zhang, Z.Q., and Yan, G.X. (1996). Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsades de pointes. J. Am. Coll. Cardiol. 28:1836-1848.
40. Fauchier, J.P., Lanfranchi, J., Ginies, G., and Raynaud, R. (1974). Syncope through multifocal ventricular tachycardia during treatment with chloroquine. Study of the hisian electrogram and treatment by verapamil. Ann. Cardiol. Angiol. 23:341-346.